ClinicalTrials.gg
RecruitingNCT04470947EXALT-2Updated Mar 22, 2024

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

An observational study in Advanced Lymphoma, Refractory Lymphoma and Refractory Leukemia, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-22.

Primary conditionLymphoma, T-CellRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, T-Cell
Why
  1. The study's listed conditions name Lymphoma, T-Cell, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medical University of Vienna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

02

Conditions studied

  • Advanced Lymphoma
  • Refractory Lymphoma
  • Refractory Leukemia
  • Refractory Acute Myeloid Leukemia
  • Refractory T-Cell Lymphoma

Browse trials for

Keywords

  • Personalized medicine
03

In context

Lymphoma, T-Cell Reclassified

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

This study's planned enrollment of 150 is below the median of 200 across 29 observational studies indexed under Lymphoma, T-Cell.

Browse Lymphoma, T-Cell studies →

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.

Compared within Lymphoma, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

150 patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma after standard treatment fulfilling inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies.
  • duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment.
  • best response to previous treatment has to be available.
  • The patient is able to give written and wishes to undergo further therapy
  • further therapy is medically feasible
  • tumor cell-containing samples can be obtained

Exclusion criteria

Exclusion Criteria:

  • current participation in another experimental clinical trial
  • performance status does not allow participation ( ˃ 1)
  • pregnancy, tested at screening
  • patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma.
  • other malignoma, diagnosed \<1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
8 Months
Patient registry
Yes

Groups and cohorts

  • Next generation functional drug screening

    Diagnostic Test: Next generation functional drug screening · Diagnostic Test: Comprehensive genomic profiling

  • Comprehensive genomic profiling

    Diagnostic Test: Next generation functional drug screening · Diagnostic Test: Comprehensive genomic profiling

  • Physician's choice

    Diagnostic Test: Next generation functional drug screening · Diagnostic Test: Comprehensive genomic profiling

Interventions

  • Diagnostic testNext generation functional drug screening

    High-throughput image based in-vitro drug screening on primary patient tumor cells

  • Diagnostic testComprehensive genomic profiling

    Comprehensive targeted profiling of genetic aberrations on primary patient tumor material

    Also known as: FoundationOne Heme

06

What researchers measure

Primary outcomes

  1. Percentage of patients with a ratio ≥1.3 of progression free survival (PFS) compared to most recent treatment

    The study aims to identify if next-generation functional drug screening (ngFDS) and/or comprehensive genomic profiling (CGP; FoundationOne®Heme) compared to physicians' choice guided treatment will have an increased percentage of patients with a ratio ≥1.3 of progression free survival (PFS)/PFS of most recent treatment in patients with aggressive haematological malignancies

    Time frame: Through study completion, an average of 8 month

Secondary outcomes

  1. Average Ratio of PFS/PFS of most prior treatment

    Average Ratio of PFS/PFS of most prior treatment

    Time frame: Through study completion, an average of 8 months

  2. Overall response rate (ORR)

    Overall response rate (ORR)

    Time frame: Through study completion, an average of 8 months

  3. Number of treatable targets identified

    Number of treatable targets identified

    Time frame: Through study completion, an average of 8 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gultekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Mullauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jager U, Staber PB, Superti-Furga G. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15. PubMed 29153976 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Mar 2026, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 14, 2020
StartActual
Jun 10, 2020
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04470947
Collaborators
Roche Pharma AG, Allcyte GmbH
Responsible party
Philipp Staber, MD, PhD (Assoc. Prof. Priv.-Doz. Dr.med.univ. Philipp Staber, Medical University of Vienna) — Principal investigator
First posted
Jul 14, 2020
Start date
Jun 10, 2020
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Mar 22, 2024

Study contacts

Philipp B. Staber, MD, PhD
Contact
philipp.staber@meduniwien.ac.at
+43 140400 ext. 73782

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion